His research interests center on the role of eicosanoids in the biology of lung cancer and pulmonary vascular diseases. In the realm of lung cancer, his work focuses on early carcinogenesis and chemoprevention. A Phase IIb trial of Iloprost demonstrated, for the first time, that airway dysplasia could be reversed in former smokers using oral Iloprost. In the area of pulmonary hypertension, he is the recipient of the NHLBI R24 for Genomics in Pulmonary Hypertension Consortium Award. He is a member of the PVDOMICS Consortium, designed to apply omics technologies for discovery of new treatments in pulmonary vascular diseases. These efforts are designed to utilize genomic, expression, metabolomic and proteomic approaches to extensively phenotyped cohorts of pulmonary hypertension patients. He is a Co-Principal Investigator on the NHLBI TOPMed award in pulmonary hypertension. TOPMed study is to generate a large set of Omic data to be used in analyses that can lead to new clinically meaningful subtypes of PVD and discover pathways for development of personalized therapies.